'Lv hypertrophy' presentation slideshows

Improving Outcomes in Heart Failure: New Insights From Vascular Biology

Improving Outcomes in Heart Failure: New Insights From Vascular Biology. Heart Failure: A Public Health Concern. 20% Lifetime risk for HF after age 40. Framingham Heart Study. Men. Women. 25. 25. 20. 20. 15. 15. Cumulative risk (%). 10. 10. 5. 5. 0. 0. 0. 40. 50. 50. 60.

636 views • 53 slides

Managing Patients with Hypertension and Heart Failure

216 views • 7 slides

Case of the week 08-15: Danon disease - A rare cause of LV hypertrophy

Case of the week 08-15: Danon disease - A rare cause of LV hypertrophy. History: 20 years old male, history of RF ablation for WPW syndrome, without prior history of heart failure. Echo : severe hypertrophy of LV with preserved global and regional function. Patient referred for CMR

166 views • 1 slides

Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease

Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease. LV: -14 g with spironolactone vs. 3 g with placebo (p < 0.01) PW velocity: -0.8 m/s vs. -0.1 m/s (p < 0.01) Systolic blood pressure: -11 mm Hg vs. -5 mm Hg (p < 0.05).

150 views • 1 slides

Case of the week 08-15: Danon disease - A rare cause of LV hypertrophy

Case of the week 08-15: Danon disease - A rare cause of LV hypertrophy. History: 20 years old male, history of RF ablation for WPW syndrome, without prior history of heart failure. Echo : severe hypertrophy of LV with preserved global and regional function. Patient referred for CMR

170 views • 1 slides